Abstract
One in five people suffer from moderate to severe chronic pain, and one in
three is unable or less able to maintain an independent lifestyle due to their
pain. Between 50 and 60 percent of people with chronic pain are less able or
unable to exercise, sleep normally, perform household chores, attend social
activities, drive a car, or walk.
The value of the pharmaceutical market for pain relief in 2007 reflects this
seeming worldwide epidemic of pain. The Global Pain Therapeutics Market
assesses key pain management therapeutics - such as opioids, triptans,
anticonvulsants, Cox-II inhibitors and traditional NSAIDs and are discussed in
terms of their past, present and future value and the role they are playing in
the effective management of pain. This report discusses the key products
within each of these areas and outlines the drivers of these markets as well
as the restraints on them.
The Global Pain Therapeutics Market also identifies and discusses trends and
issues that will have a significant impact on the pain management market and
profiles the leading companies in the field. The report provides the reader
with valuable information and analysis regarding key products on the market
and in clinical development.
This 408-page report includes 96 profiles of companies engaged in the
development and/or commercialization of pain therapeutics and over 160 tables
and graphs illustrating sales trends, past and present, as well as pipelines
and demographic and market trends in the area of pain management.
Key features and highlights of this report:
- Extensive review of key products indicated for pain conditions and their
market value and impact
- Discussion of the key drivers of and restraints on the global pain
therapeutics market
- Qualitative analysis of key pain markets and products driving growth
(opioids, NSAIDs, triptans, neuropathic pain therapies (anticonvulsants) and
Cox-II inhibitors)
- Profiles and reviews of key pipeline products in development for
fibromyalgia, cancer pain, post-operative pain, migraine pain, neuropathic
pain and opioid therapies
- Profiles of nearly 100 companies engaged in the development and/or
commercialization of pain therapeutics worldwide
- Overviews of treatment options for post-operative pain, migraine pain,
cancer pain, fibromyalgia, arthritic pain, back pain, neuropathic pain, and
the demographic impact of these conditions.
- Chapter devoted to the role of drug delivery technologies in the current
and future treatment of pain
- Discussion of promising areas of research in a variety of pain areas and
companies engaged in cutting edge research and development
Key questions answered in this report:
- What is the current state of the global pain therapeutics market?
- How has the Cox-II debacle effected the market for and treatment of pain
conditions?
- What pain therapies, old and new, are today proving their market and
clinical value?
- What new classes of pain therapeutics are in clinical development and
which classes and therapies are demonstrating superior efficacy?
- Which diseases and conditions have the most room for growth in terms of
unmet need and market demand?
View Cart
